As a valued subscriber to one of AHC Media’s vast library of resources, we are sending this reminder that your new issue is now available online. The articles in this issue are listed below:
There are more similarities than differences among the seven currently available glucagon-like peptide-1 (GLP-1) receptor agonists. The most recently FDA-approved GLP-1 receptor agonist, once-weekly semaglutide (Ozempic), was compared in a head-to-head trial to once-weekly exenatide-ER (Bydureon).
Might direct oral coagulants offer some advantage for extended venous thromboembolism (VTE) thromboprophylaxis in patients undergoing knee or hip arthroplasty who are known to suffer an increased risk of VTE in the immediate postoperative period?
The diversity of treatment options currently available should stimulate optimism that the consequences of obstructive sleep apnea can be improved successfully in most patients.
The proportion of patients who succumb to influenza pneumonia vs. those who incur bacterial pneumonia subsequent to pneumonia vs. all other incident pneumonias that occur concomitantly with flu season is not readily discernible.
Financial Disclosure: To reveal any potential bias in this publication, and in accordance with Accreditation Council for Continuing Medical Education guidelines, Dr. Brunton reports he is a retained consultant for Abbott Diabetes, Becton Dickinson, Boehringer Ingelheim, Janssen, Lilly, Merck, Novo Nordisk, and Sanofi; he serves on the speakers bureau of AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, and Novo Nordisk. Dr. Kuritzky (author) is a consultant for and on the speakers bureau of Amgen, Boehringer Ingelheim, and Shire. Ms. Coplin, Mr. Springston, and Editorial Group Manager Terrey L. Hatcher report no financial relationships relevant to this field of study.
